Advanced Search

 

Study ID Status Title Patient Level Data
AZL10002 Completed An Evaluation of the Steady-State Pharmacokinetics of abacavir, lamivudine, and zidovudine following administration of a Combined Formulated Tablet (300/150/300mg abacavir/lamivudine/zidovudine) versus ZIAGEN (300mg abacavir) and COMBIVIR (150/300mg lamivudine/zidovudine) in Subjects with HIV-1 ...
AZL30002 Completed A Phase IIIb, Randomised, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of a Triple Combination Tablet (Trizivir) [abacavir, lamivudine, zidovudine] Versus Continued Antiretroviral Triple Therapy in HIV-1 Infected Subjects with Undetectable Plasma HIV-1 RNA Levels (TRIZAL)
AZL30004 Completed A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of TRIZIVIR plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for 24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR ...
AZL30004_1 Completed A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability ofTRIZIVIR. plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR ...
AZL30006 Completed A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg twice daily or 700mg/100mg twice daily) When Used in Combination with a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR twice daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.
AZL40001 Completed An open-label, single arm, multicentre, pilot phase IV study to evaluate the efficacy and safety of a potent combination therapy (Trizivir + Efavirenz) in antiretroviral nave adults with a CD4+ cell count <200mm3 over a 48-week treatment period (TETRA Trizivir Efavirenz TReAtment)
AZLF3002 Completed Multicentre, open-label, pilot study to evaluate the efficacy and safety of a triple therapy combining AZT/3TC/ABC as a combined tablet of Trizivir, in HIV-infected patients with an undetectable viral load after quadruple therapy (COM, ABC, EFV) during CNAF 3008 study (La Francilienne).
AZLF3004 Completed An Open-label study to evaluate long-term (48 weeks) safety and efficacy of switch to TRIZIVIR after first line quadruple induction therapy: AZLF3004-Trisud
B04-689PK-P05P2 Completed A two-way, steady-state, fasting, dosage form proportionality study of 150 mg Wellbutrin XL™ tablets and 450 mg bupropion extended-release tablets in normal healthy non-smoking male and female subjects.
B04-696PK-P05P2 Completed A two-way, steady-state, fasting, dosage form proportionality study of 150 mg Wellbutrin XL™ tablets and 450 mg bupropion extended-release tablets in normal healthy non-smoking male and female subjects.
B2A10001 Completed A randomised, double blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of single inhaled doses of a new chemical entity in healthy male subjects. Study Listed on ClinicalStudyDataRequest.com
B2A10002 Completed A multi-centre, randomised, double-blind, placebo controlled, crossover study to examine the efficacy, safety, tolerability and systemic pharmacokinetics of single inhaled dose of a new chemical entity in asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
B2B10001 Completed A randomised, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single inhaled doses of GW678007 in healthy male subjects. Study Listed on ClinicalStudyDataRequest.com
B2B10002 Completed A multi-centre, randomized, double-blind, double dummy, placebo-controlled, 5-period crossover study to examine the safety, tolerability, systemic pharmacodynamics, and systemic pharmacokinetics of single inhaled doses of a new chemical entity in asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
B2C10001 Completed A randomised, double blind, placebo controlled study to examine the safety, tolerability, pharmacodynamics and systemic pharmacokinetic profile of single inhaled doses of GW642444 in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
B2C101762 Completed A multi-centre, randomised, double-blind, placebo controlled, dose ascending, four way crossover study to examine efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat doses of GW642444 Study Listed on ClinicalStudyDataRequest.com
B2C104604 Completed A randomised, double-blind, placebo-controlled, dose ascending, five-way crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 µg) of GW642444M Study Listed on ClinicalStudyDataRequest.com
B2C106093 Completed Multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (25, 100 and 400 mcg once daily) of GW642444 Study Listed on ClinicalStudyDataRequest.com
B2C106180 Completed A single-centre, open-label, sequential, dose-ascending study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of single intravenous, inhaled and oral doses of GW642444 in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
B2C106996 Completed A randomized, single-dose, dose-ascending, double blind, placebo-controlled, 5-way crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in asthmatic patients Study Listed on ClinicalStudyDataRequest.com
B2C108562 Completed A 2-wk study to evaluate the safety, tolerability,pharmacodynamics and pharmacokinetics of GW642444H(100 administered once daily in the morning via DISKUS™ dry-powder inhaler)compared with SEREVENT(salmeterol)(50mcg administered twice daily via DISKUS dry-powder inhaler)and placebo in subject w/COPD Study Listed on ClinicalStudyDataRequest.com
B2C108784 Completed A randomised, double-blind, placebo-controlled, parallel-group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and extra-pulmonary pharmacodynamics of inhaled doses of GW642444M formulated with magnesium stearate in healthy subjects Study Listed on ClinicalStudyDataRequest.com
B2C109575 Completed A randomised, double-blind, placebo controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma Study Listed on ClinicalStudyDataRequest.com
B2C110165 Completed A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in COPD patients. Study Listed on ClinicalStudyDataRequest.com
B2C111045 Completed Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.